Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo.
Drug maker Pfenex announced this week that it has completed its comparative use human factors study for its follow-on teriparatide product, PF708, referencing the osteoporosis drug Forteo. The follow-on was approved by the FDA earlier this month.
According to Pfenex, the study included 102 untrained participants, 52 of whom were patients with osteoporosis and 50 of whom were caregivers. Of the 18 critical tasks assessed, patients using the follow-on had fewer user errors or the same number of errors for 12 (67%) of those tasks. Among caregivers, there were equal numbers of user errors or fewer errors for 15 (83%) of the tasks.
No error difference, in either of the user groups, exceeded the prespecified maximum allowable difference.
In a statement, Pfenex’s chief executive officer, Eef Schimmelpennink, said that the outcome of the study “demonstrates noninferiority between the user interfaces of our product and Forteo,” and that the company will present the data to the FDA as part of a package that the regulator will review to evaluate therapeutic equivalence of the product with its reference.
Because PF708 was approved under the 505(b)(2) approval pathway instead of the biosimilar approval pathway, Pfenex can seek pharmacy-level substitutability for the product without having to undertake the kinds of extra clinical studies that a biosimilar would be subject to if seeking an interchangeable designation; because it is a follow-on and not a biosimilar, PF708 will be evaluated for a determination therapeutic equivalence rather than an interchangeable designation.
When the follow-on was first approved, Schimmelpennink noted that, in order to optimize patient and payer impact, Pfenex’s partner Alvogen will launch PF708 once the FDA has made its decision on therapeutic equivalence for the product.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.